Acutus Medical, Inc. (NASDAQ: AFIB) (“Acutus”) today announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares of common stock are being offered by Acutus. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Acutus, are expected to be $77.0 million. The offering is expected to close on July 19, 2021, subject to the satisfaction of customary closing conditions. In addition, Acutus has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of Acutus’ common stock at the price to the public, less underwriting discounts and commissions.

Goldman Sachs & Co. LLC is acting as sole book-running manager for the offering.

The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or by email at [email protected].

A registration statement, including a preliminary prospectus, relating to these securities has been filed with the U.S. Securities and Exchange Commission and was declared effective on July 14, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.